Core-cross-linked polymeric micelles: a versatile nanomedicine platform with broad applicability

Q. Hu

Research output: ThesisPhD Thesis - Research external, graduation UTAcademic

137 Downloads (Pure)

Abstract

This dissertation addresses the broad applicability of the nanomedicine platform core-cross-linked polymeric micelles (CCL-PMs) composed of thermosensitive mPEG-b-pHPMAmLacn block copolymers. In Chapter 1, a general introduction to nanomedicines is provided, with a particular focus on polymeric nanoparticles. In Chapter 2, the high tuneability of CCL-PMs with respect to particle size and carrier degradation characteristics is described, which can be achieved by modulating the molecular weight of the constituting block copolymer and the cross-linking, respectively. In addition, drug molecules can be covalently attached to the core of CCL-PMs via hydrolysable linkages, which allow the native drug to be released at a controllable rate under physiological conditions. By altering the hydrolytic sensitivity of these linkages, the release profile of drug from the CCL-PMs can be completely tuned (Chapter 2). In Chapter 3, the anticancer agent docetaxel was covalently entrapped in CCL-PMs and the therapeutic performance of the obtained nanomedicine was evaluated in vivo. Compared to the marketed formulation Taxotere®, docetaxel-entrapped CCL-PMs demonstrated superior antitumour efficacy and tolerability in rodents. In particular, a single intravenous dose of docetaxel-entrapped CCL-PMs resulted in complete regression of breast tumours in mice, leading to 100% survival of the animals. Besides small molecule drugs, a model therapeutic peptide, leuprolide, was covalently entrapped in CCL-PMs (Chapter 4). Compared to the soluble peptide, leuprolide entrapped in CCL-PMs showed a prolonged circulation profile in healthy rats and the leuprolide released from circulating CCL-PMs remained biologically active, as demonstrated by the change of plasma levels of testosterone in the animals. Further, in Chapter 5, the feasibility of subcutaneous administration of CCL-PMs is addressed, as the subcutaneous route is potentially more patient-friendly and cost-effective than the intravenous route. The model drugs either dexamethasone or paclitaxel was covalently entrapped in CCL-PMs, which were injected to healthy mice following intravenous and subcutaneous route of administration. Importantly, subcutaneous administration of drug-containing CCL-PMs resulted in high systemic availability, demonstrating subcutaneous delivery as a promising route to administer nanomedicines based on CCL-PMs. At the end, Chapter 6 summarises the results described in this dissertation and provides perspectives on the use of this nanomedicine platform based on CCL-PMs.
Original languageEnglish
Awarding Institution
  • University of Twente
Supervisors/Advisors
  • Storm, G. , Supervisor
  • Prakash, J. , Advisor
  • Hennink, W.E., Supervisor
Award date29 Oct 2015
Place of PublicationEnschede
Publisher
Print ISBNs978-90-365-3947-0
DOIs
Publication statusPublished - 29 Oct 2015

Fingerprint

Medical nanotechnology
Micelles
docetaxel
Leuprolide
Pharmaceutical Preparations
Block copolymers
Animals
Peptides
Molecules
Paclitaxel
Antineoplastic Agents
Dexamethasone
Testosterone

Keywords

  • METIS-312092
  • IR-97576

Cite this

@phdthesis{0901163088b1470282c705f227c5ed7b,
title = "Core-cross-linked polymeric micelles: a versatile nanomedicine platform with broad applicability",
abstract = "This dissertation addresses the broad applicability of the nanomedicine platform core-cross-linked polymeric micelles (CCL-PMs) composed of thermosensitive mPEG-b-pHPMAmLacn block copolymers. In Chapter 1, a general introduction to nanomedicines is provided, with a particular focus on polymeric nanoparticles. In Chapter 2, the high tuneability of CCL-PMs with respect to particle size and carrier degradation characteristics is described, which can be achieved by modulating the molecular weight of the constituting block copolymer and the cross-linking, respectively. In addition, drug molecules can be covalently attached to the core of CCL-PMs via hydrolysable linkages, which allow the native drug to be released at a controllable rate under physiological conditions. By altering the hydrolytic sensitivity of these linkages, the release profile of drug from the CCL-PMs can be completely tuned (Chapter 2). In Chapter 3, the anticancer agent docetaxel was covalently entrapped in CCL-PMs and the therapeutic performance of the obtained nanomedicine was evaluated in vivo. Compared to the marketed formulation Taxotere{\circledR}, docetaxel-entrapped CCL-PMs demonstrated superior antitumour efficacy and tolerability in rodents. In particular, a single intravenous dose of docetaxel-entrapped CCL-PMs resulted in complete regression of breast tumours in mice, leading to 100{\%} survival of the animals. Besides small molecule drugs, a model therapeutic peptide, leuprolide, was covalently entrapped in CCL-PMs (Chapter 4). Compared to the soluble peptide, leuprolide entrapped in CCL-PMs showed a prolonged circulation profile in healthy rats and the leuprolide released from circulating CCL-PMs remained biologically active, as demonstrated by the change of plasma levels of testosterone in the animals. Further, in Chapter 5, the feasibility of subcutaneous administration of CCL-PMs is addressed, as the subcutaneous route is potentially more patient-friendly and cost-effective than the intravenous route. The model drugs either dexamethasone or paclitaxel was covalently entrapped in CCL-PMs, which were injected to healthy mice following intravenous and subcutaneous route of administration. Importantly, subcutaneous administration of drug-containing CCL-PMs resulted in high systemic availability, demonstrating subcutaneous delivery as a promising route to administer nanomedicines based on CCL-PMs. At the end, Chapter 6 summarises the results described in this dissertation and provides perspectives on the use of this nanomedicine platform based on CCL-PMs.",
keywords = "METIS-312092, IR-97576",
author = "Q. Hu",
year = "2015",
month = "10",
day = "29",
doi = "10.3990/1.9789036539470",
language = "English",
isbn = "978-90-365-3947-0",
publisher = "Universiteit Twente",
school = "University of Twente",

}

Core-cross-linked polymeric micelles: a versatile nanomedicine platform with broad applicability. / Hu, Q.

Enschede : Universiteit Twente, 2015. 206 p.

Research output: ThesisPhD Thesis - Research external, graduation UTAcademic

TY - THES

T1 - Core-cross-linked polymeric micelles: a versatile nanomedicine platform with broad applicability

AU - Hu, Q.

PY - 2015/10/29

Y1 - 2015/10/29

N2 - This dissertation addresses the broad applicability of the nanomedicine platform core-cross-linked polymeric micelles (CCL-PMs) composed of thermosensitive mPEG-b-pHPMAmLacn block copolymers. In Chapter 1, a general introduction to nanomedicines is provided, with a particular focus on polymeric nanoparticles. In Chapter 2, the high tuneability of CCL-PMs with respect to particle size and carrier degradation characteristics is described, which can be achieved by modulating the molecular weight of the constituting block copolymer and the cross-linking, respectively. In addition, drug molecules can be covalently attached to the core of CCL-PMs via hydrolysable linkages, which allow the native drug to be released at a controllable rate under physiological conditions. By altering the hydrolytic sensitivity of these linkages, the release profile of drug from the CCL-PMs can be completely tuned (Chapter 2). In Chapter 3, the anticancer agent docetaxel was covalently entrapped in CCL-PMs and the therapeutic performance of the obtained nanomedicine was evaluated in vivo. Compared to the marketed formulation Taxotere®, docetaxel-entrapped CCL-PMs demonstrated superior antitumour efficacy and tolerability in rodents. In particular, a single intravenous dose of docetaxel-entrapped CCL-PMs resulted in complete regression of breast tumours in mice, leading to 100% survival of the animals. Besides small molecule drugs, a model therapeutic peptide, leuprolide, was covalently entrapped in CCL-PMs (Chapter 4). Compared to the soluble peptide, leuprolide entrapped in CCL-PMs showed a prolonged circulation profile in healthy rats and the leuprolide released from circulating CCL-PMs remained biologically active, as demonstrated by the change of plasma levels of testosterone in the animals. Further, in Chapter 5, the feasibility of subcutaneous administration of CCL-PMs is addressed, as the subcutaneous route is potentially more patient-friendly and cost-effective than the intravenous route. The model drugs either dexamethasone or paclitaxel was covalently entrapped in CCL-PMs, which were injected to healthy mice following intravenous and subcutaneous route of administration. Importantly, subcutaneous administration of drug-containing CCL-PMs resulted in high systemic availability, demonstrating subcutaneous delivery as a promising route to administer nanomedicines based on CCL-PMs. At the end, Chapter 6 summarises the results described in this dissertation and provides perspectives on the use of this nanomedicine platform based on CCL-PMs.

AB - This dissertation addresses the broad applicability of the nanomedicine platform core-cross-linked polymeric micelles (CCL-PMs) composed of thermosensitive mPEG-b-pHPMAmLacn block copolymers. In Chapter 1, a general introduction to nanomedicines is provided, with a particular focus on polymeric nanoparticles. In Chapter 2, the high tuneability of CCL-PMs with respect to particle size and carrier degradation characteristics is described, which can be achieved by modulating the molecular weight of the constituting block copolymer and the cross-linking, respectively. In addition, drug molecules can be covalently attached to the core of CCL-PMs via hydrolysable linkages, which allow the native drug to be released at a controllable rate under physiological conditions. By altering the hydrolytic sensitivity of these linkages, the release profile of drug from the CCL-PMs can be completely tuned (Chapter 2). In Chapter 3, the anticancer agent docetaxel was covalently entrapped in CCL-PMs and the therapeutic performance of the obtained nanomedicine was evaluated in vivo. Compared to the marketed formulation Taxotere®, docetaxel-entrapped CCL-PMs demonstrated superior antitumour efficacy and tolerability in rodents. In particular, a single intravenous dose of docetaxel-entrapped CCL-PMs resulted in complete regression of breast tumours in mice, leading to 100% survival of the animals. Besides small molecule drugs, a model therapeutic peptide, leuprolide, was covalently entrapped in CCL-PMs (Chapter 4). Compared to the soluble peptide, leuprolide entrapped in CCL-PMs showed a prolonged circulation profile in healthy rats and the leuprolide released from circulating CCL-PMs remained biologically active, as demonstrated by the change of plasma levels of testosterone in the animals. Further, in Chapter 5, the feasibility of subcutaneous administration of CCL-PMs is addressed, as the subcutaneous route is potentially more patient-friendly and cost-effective than the intravenous route. The model drugs either dexamethasone or paclitaxel was covalently entrapped in CCL-PMs, which were injected to healthy mice following intravenous and subcutaneous route of administration. Importantly, subcutaneous administration of drug-containing CCL-PMs resulted in high systemic availability, demonstrating subcutaneous delivery as a promising route to administer nanomedicines based on CCL-PMs. At the end, Chapter 6 summarises the results described in this dissertation and provides perspectives on the use of this nanomedicine platform based on CCL-PMs.

KW - METIS-312092

KW - IR-97576

U2 - 10.3990/1.9789036539470

DO - 10.3990/1.9789036539470

M3 - PhD Thesis - Research external, graduation UT

SN - 978-90-365-3947-0

PB - Universiteit Twente

CY - Enschede

ER -